Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580229 · ClinicalTrials.gov registry record · Phase 2
A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.
A Phase 2 study of Rheumatoid Arthritis, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT00580229: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by University of South Florida.
NCT00580229 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by University of South Florida. The registered enrollment target is 50 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00580229, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will be an open-label prospective analysis of oral prednisone (compared to IV methylprednisolone) as a pre-treatment for rituximab in patients with rheumatoid arthritis. The study will be useful as pilot data to establish that there are no different trends between the two treatment strategies at decreasing the frequency and severity of acute infusion reactions. It would also establish proof of principle that pre-treatment with oral prednisone is equally as efficacious as IV methylprednisolone. The primary endpoint will be to assess the safety and tolerability of rituximab (Rituxan) in RA. By showing that there are no differences in the frequency or severity of acute infusion reactions after rituximab when using pre-treatment with oral prednisone compared to I.V. methylprednisolone, we will establish proof of principle that oral prednisone is a viable alternative to I.V. methylprednisolone. Pre-treatment with oral prednisone would be a practical advantage for both the patient and the treating physician. The patient could self-administer this treatment at home thereby decreasing the time they would need to spend at the infusion center. Further, this dose of prednisone has fewer side effects than 100mg of methylprednisolone.
Primary Outcome
Open-label assessment of AIR's during and/or within 24 hours in patients pretreated with 40mg oral prednisone 30 minutes prior to initial rituximab infusion
Conditions Studied
Interventions
- DRUG prednisone
Study Locations (2)
Florida
- Arthritis Research of Florida, Inc. - Palm Harbor
- University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT00580229 record still lists
NCT00580229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which prednisone is the first listed.
NCT00580229 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00580229 about?
NCT00580229 is a clinical study titled "A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.". This study will be an open-label prospective analysis of oral prednisone (compared to IV methylprednisolone) as a pre-treatment for rituximab in patients with rheumatoid arthritis. The study will be useful as pilot data to establish that there are no different trends between the two treatment strate...
What is the current status of trial NCT00580229?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-12. Estimated completion is 2011-12.
What conditions does trial NCT00580229 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00580229?
The interventions under investigation include: prednisone (DRUG).
Who is sponsoring clinical trial NCT00580229?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00580229 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00580229's enrollment target sits among peer trials
50 140th of 197 higher than 56 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia